The impact of Tegillarca granosa extract
haishengsu on HL-60 cell

• Authors: Jinshen Wang , Lixia Wei , Yueqin Han , Daogang Qin , Qiaozhi Yang , Xiuli Ju
• Languages of publication: EN

Abstracts

EN

Haishengsu (Hss) is a purified protein from
Tegillarca granosa that has been used as a traditional
Chinese medicine to treat cancer for more than a century.
In this study, we observed the impact of Haishengsu (Hss)
on the proliferation and differentiation of HL-60 cells in
the leukemic cell line by taking tretinoin and AS2O3 as
a positive control and making a comparative analysis
between the effect of Hss and tretinoin and AS2O3. We
found that Hss could significantly inhibit the proliferation
of HL-60 cells and caused most of the cells to stay in
the G0/G1 phase. Its effect was much stronger than that of
tretinoin and AS2O3, and the ability of Hss to induce differentiation
was close to tretinoin. Hss functions probably
by inhibiting the expression of the Bcl-2 and MPO genes
and further promoting the expression of the Bax gene. Hss
has a significant effect on both inhibiting the proliferation
and inducing the differentiation of HL-60 cells. It is possible
that Hss may be a new kind of clinical differentiation
inducer.

Keywords

EN

Tegillarca granosa; Cell differentiation; Leukemia

• Publisher: De Gruyter Open
• Journal: Open Medicine
• Year: 2014
• Volume: 10
• Issue: 1

Dates

accepted

25 - 5 - 2015

online

3 - 8 - 2015

received

6 - 4 - 2015

Contributors

author

Jinshen Wang

• Department of Pediatric Hematology,
  Qilu Hospital, Shandong University, 107 West Wenhua Rd, Jinan,
  Shandong 250012, China
• Department of Pediatric, Liaocheng People’s Hospital, Liaocheng,
  Shandong, 252000, P.R.China

author

Lixia Wei

• Department of Pediatric, Liaocheng People’s Hospital, Liaocheng,
  Shandong, 252000, P.R.China

author

Yueqin Han

• Department of Pediatric, Liaocheng People’s Hospital, Liaocheng,
  Shandong, 252000, P.R.China

author

Daogang Qin

• Department of Pediatric, Liaocheng People’s Hospital, Liaocheng,
  Shandong, 252000, P.R.China

author

Qiaozhi Yang

• Department of Pediatric, Liaocheng People’s Hospital, Liaocheng,
  Shandong, 252000, P.R.China

author

Xiuli Ju

• Department of Pediatric Hematology,
  Qilu Hospital, Shandong University, 107 West Wenhua Rd, Jinan,
  Shandong 250012, China
• Cryomedicine Laboratory of Qilu Hospital of Shandong University,
  Jinan, Shandong, 250000, P.R.China

References

• ---
• [1] Dassonneville L, Wattez N, Baldeyrou B, Mahieu C, Lansiaux A,Banaigs B, et al. Inhibition of topoisomerase II by the marinealkaloid ascididemin and induction of apoptosis in leukemiacells. Biochem Pharmacol 2000, 60: 527-537
• [2] Wang S, Wang Z, Grant S. Bryostatin 1 and UCN-01 potentiate1-beta-D-arabinofuranosylcytosine-induced apoptosis inhuman myeloid leukemia cells through disparate mechanisms.Mol Pharmacol 2003, 63 : 232-242
• [3] Li GY, Liu JZ, Zhang B, Yang M, Chen SG, Hou M, et al. Tegillarcagranosa extract Haishengsu (HSS) suppresses expression ofmdr1, BCR/ABL and sorcin in drug-resistant K562/ADM tumorsin mice. Adv Med Sci. 2013;58:112-117
• [4] Xu W, Chang Z, Liu X, Jiang C, Wang C, Xu L. Antitumor effectsof a polypeptide isolated from Tegillarca granosa linnaeusand the related molecular mechanism. Pak J Pharm Sci.2014;27:565-570
• [5] Chen ZX, Xue YQ, Zhang R, Tao RF, Xia XM, Li C, et al. A clinicaland experimental study on all-trans retinoic acid-treated acutepromyelocytic leukemia patients. Blood 1991;78:1413-1419
• [6] Chen SJ, Chen Z, Chen A, Tong JH, Dong S, Wang ZY, et al.Occurrence of distinct PML-RARα fusion gene isoforms inpatients with acute promyelocytic leukemia detected byreverse trascriptase/polymerase chain reaction.Oncogene1992;7:1223-1232
• [7] Pandolfi PP, Alcalay M, Fagioli M, Zangrilli D, Mencarelli A,Diverio D, et al. Genomic variability and alternative splicinggenerate multiple PML/ RARα transcripts that encode aberrantPML proteins and PML/ RARα isoforms in acute promyelocyticleukemia.EMBO 1992,11:1397-1407
• [8] Wang ZY. Mechanism of action of all-trans retinoic acid andarsenic trioxide in the treatment of acute promyelocyticleukemia. Gan To Kagaku Ryoho, 2002,Suppl 1: 214-218
• [9] Halftermeyer J, Le Bras M, De Thé H． RXR, a key member ofthe oncogenic complex in acute promyelocytic leukemia.MedSci(Paris),2011, 27(11):973-978[WoS]
• [10] Chamarin N, Smith GB, Green A, Andrews MI. Retinoic acidsyndrome. Lancet 1993; 341:1289-1290
• [11] Wang ZY, Chen Z. Acute promyelocytic leukemia: from highlyfatal to highly curable. Blood,2008,111,2505-2515[WoS]
• [12] Tan SM, Hyland RH, Al-Shamkhani A, Douglass WA, Shaw JM,Law SK. Effect of integrin beta 2 subunit trun cations on LFA-1(CD11 a/CD18 ) and Mac-1 (CD11b /CD18) assembly, surfaceexpression, and function. Immuno, 2000; 165: 2574-2581
• [13] Paietta E, Goloubeva O, Neuberg D, Bennett JM, GallagherR, Racevskis J, et al. A surrogate marker profile for PML/RAR alpha expressing acute promyelocytic leukemia and theassociation of immunophenotypic markers with morphologicand molecular subtypes. Cytometry B Clin Cytom,2004 59:1-9[Crossref]
• [14] Alvarado CS, Austin GE, Borowitz MJ, Shuster JJ, CarrollAJ, Austin ED, et al.Myelopeorxidase gene expression ininfant leukemia:a Pediatric oncology Group Study. LekuLymPhoma,1998,29:145-160
• [15] Serrano J, Román J, Sánchez J, Torres A.Myeloperoxidase geneexpression in acute lymphblastic lekuemia.Br J Haematol,1997; 97:841-843
• [16] Eskes R, Desagher S, Antonsson B, Martinou JC. Bid inducesthe oligomerization and insertion of Bax into the outermitochondrial membrane. Mol Cell Biol, 2000, 20:929-935
• [17] Miramar MD, Costantini P, Ravagnan L, Saraiva LM, HaouziD, Brothers G, et al. NADH oxidase activity of mitochondrialapoptosis-inducing factor. J Biol Chem, 2001 ,276 : 16391-163981

Identifiers

DOI

10.1515/med-2015-0048